3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Squamous Cell Carcinoma of Head and Neck
11
Small Cell Lung Carcinoma
11
Lung Neoplasms
11
Neoplasm Metastasis
10
Carcinoma, Hepatocellular
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Advanced Solid Tumors
7
Melanoma
6
Biliary Tract Neoplasms
6
Urinary Bladder Neoplasms
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Carcinoma, Renal Cell
4
Stomach Neoplasms
3
Recurrence
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Advanced Solid Tumours
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Solid Tumor
2
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Rutin
1
Gemcitabine
1
Cisplatin
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Muscle Invasive Bladder Cancer
×
durvalumab
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled